Effects of serum 25-hydroxyvitamin D level on decreased bone mineral density at femoral neck and total hip in Chinese type 2 diabetes

Liting Guo1☯, Zhihong Gao2☯*, Huanqi Ge1☯*

1 Department of Endocrinology, Teda International Cardiovascular Hospital, Tianjin, China, 2 Department of Endocrinology, General Hospital of Tianjin Medical University, Tianjin, China

☯ These authors contributed equally to this work.
* zhg2831@163.com (ZHG); Gehuanqi@163.com (HQG)

Abstract

Objective
The aims of this study is to observe the levels of serum 25-hydroxyvitamin D (25OHD), parathyroid hormone and bone mineral density (BMD) in type 2 diabetes as well as to analyze the correlationship between 25OHD level and BMD.

Methods
The subjects included 368 type 2 diabetic patients, ages ranged 40–79 years and 300 non-diabetic control subjects matched for age, gender and body mass index. The serum 25OHD concentration, parathyroid hormone level and BMDs value at lumbar spine (L1-L4), femoral neck, total hip and total body were measured. The BMDs (g/cm²) was measured by LUNAR’s DEXA dual-energy X-ray absorptiometry.

Results
① Compared with control subjects, the serum 25OHD level, BMDs at the femoral neck and total hip declined in type 2 diabetes [(45±17 vs. 36±12 nmol/L), (0.93±0.17 vs. 0.85±0.14 g/cm²), (0.93±0.14 vs. 0.87±0.15g/cm²) (all P<0.05)]; The parathyroid hormone level in type 2 diabetes was higher in type 2 diabetes than that in control subjects (8.5±4.2 vs. 5.6±3.9 pmol/L) (P<0.05).

② Compared with diabetes duration ≤10 years group, BMDs at the femoral neck and total hip decreased in diabetes duration >10 years group [(0.88±0.11 vs. 0.81±0.15 g/cm²), (0.91±0.14 vs. 0.84±0.16 g/cm²)(All P<0.05)]; The parathyroid hormone level increased in diabetes duration >10 years group than diabetes duration ≤10 years group (10.6±9.1 vs. 7.1±3.7 pmol/L) (P<0.05).

③ Compared with hemoglobin A1c (HbA1c) ≤8% group, 25OHD and BMDs at the femoral neck and total hip in HbA1c >8% group decreased [(40±15 vs. 32±13 nmol/L), (0.89±0.13 vs. 0.83±0.13 g/cm²), (0.95±0.13 vs. 0.83±0.16 g/cm²) (All P<0.05)] and the parathyroid hormone level increased (7.2±4.0 vs. 10.0±8.8 pmol/L) (P<0.05).
④ The morbidity of diabetic osteoporosis and osteopenia (41.0%, 47.8%) were higher than those in control subjects (27.0%, 33.3%) ($\chi^2 = 4.37$ and 4.70, $P = 0.04$ and 0.03); Diabetes duration, HbA1c and parathyroid hormone levels were longer or higher in Diabetic osteoporosis group than those in normal BMD group and osteopenia group (All $p < 0.05$).

⑤ Simple factor correlation analysis showed that the BMD at the femoral neck was negatively correlated with the age, diabetes duration, HbA1c, parathyroid hormone ($r_s = -0.18$, $-0.23$, $-0.18$, $-0.25$), and positively correlated with 25OHD ($r_s = 0.23$).

Conclusions
Decreased BMDs and increased incidence of osteoporosis were observed in type 2 diabetic patients, which are closely related to the serum 25OHD level. These findings were more prominent at the femoral neck and total hip for patients with a longer diabetic history and poor glycemic control.

Introduction
Diabetes mellitus and osteoporosis are the two most common diseases in elderly individuals [1, 2]. Osteoporosis is a systemic skeletal disorder characterized by impaired bone quality and microstructural deterioration, resulting in the increased likelihood of bone fracture [3]. This is a significant social health problem for middle-age and elderly individuals. A recent study [4] reported that over 10 million adults have osteoporosis and nearly 43 million have decreased bone density. In China, the incidence of osteoporosis is approximately 20% for patients older than 40 years of age [5]. Presently, the awareness of and treatment for osteoporosis is very low, therefore research on osteoporosis is attracting more attention.

There is confirmed evidence that there is an association between diabetes and bone metabolism. The incidence of osteoporosis and fractures in diabetic (types 1 and 2) patients was higher than those in non-diabetic subjects, especially in the decreased bone mineral density (BMD) population [6–9]. Koh [10] showed that the fracture risk at the spine and hip increased 1.7–2.2-fold in type 2 diabetes compared with control subjects, and the fracture risk increased 2.5–3.4-fold when the diabetes duration was greater than 15 years.

Another risk factor for fracture may be hypovitaminosis D, as established for the general population [11–13]. Vitamin D has an important effect on bone metabolism, which is formed in the epidermis or provided by the diet. Heike [14] showed a positive association between vitamin D status and BMD at the femoral neck. Compared with subjects with vitamin D deficiency, those with vitamin D insufficient subjects had a 7.3% higher BMD and vitamin D replete subjects had an 8.5% higher BMD. In addition, vitamin D deficiency may indirectly increase risk of diabetes progression by contributing to low bone density.

Lower BMD is a primary risk factor for higher risk of fracture [14–17]. Each standard deviation of decreased BMD yields a 3-fold increase in fracture risk [18]. Previously, decreased BMD has been recognized in type 1 diabetes [19]. However, there has been controversy over its trend in type 2 diabetes. Several studies have suggested that type 2 diabetes is associated with a decreased BMD [4, 20], while other studies report a normal or increased BMD in type 2 diabetes [21–23]. This study detected the serum 25-hydroxyvitamin D concentration, parathyroid hormone level and evaluated the BMDs value at the lumbar spine (L1-L4), femoral neck,
total hip and total body in all subjects to evaluate their levels in type 2 diabetes and to explore the correlativity factors of decreased BMD.

**Subjects and methods**

Three hundred and sixty-eight patients with type 2 diabetes were randomly selected at the endocrinology department of General Hospital in Tianjin Medical University and Teda International Cardiovascular Hospital in Tianjin from January 2014 to June 2016. The subjects included 121 males and 247 females. The ages of subjects ranged from 40–79. At the same time, three hundred non-diabetic subjects were selected matched for age, gender, Body Mass Index (BMI) and history of smoking and alcoholism at the two hospitals mentioned above. The study protocol was approved by the Independent Ethics Committee (IEC) of Teda International Cardiovascular Hospital. All subjects gave written consent for participation. The supplementary registration institution is Chinese Clinical Trial Registry, and registration number is ChiCTR-ROC-17010468. I am sorry to say, we did not register before participant recruitment due to my work negligence.

Inclusion criteria

Type 2 diabetes mellitus conformed to the 1999 WHO Diagnostic Criteria. Non-diabetic subjects had a normal blood sugar, blood lipids and blood pressure.

Exclusion criteria

Subjects excluded with hyperthyroidism, hyperparathyroidism and Paget’s disease. Subjects receiving corticosteroids, gonadal hormones, immunosuppressant or anticonvulsants medications were excluded from both groups. Subjects on thiazolidinediones from diabetes group were also excluded. Subjects with severe hepatopathy, nephropathy and neoplastic diseases were also excluded. Subjects did not take drugs affecting bone metabolism (such as vitamin D and its derivatives, calcium, diphosphonate) within six months. No female subjects were pregnant or lactating.

BMD measurements

The BMDs (g/cm$^2$) at the lumbar spine (L1-L4), femoral neck, total hip, and whole body were measured by LUNAR’s DEXA dual-energy X-ray absorptiometry. To eliminate technical variation, the same operator measured all subjects. The values of lumbar spine BMD were presented as the mean of the L1-L4. T scores were calculated on the basis of the normal reference values in the age and gender-matched Chinese group. Based on the WHO diagnostic criteria, patients were diagnosed with osteoporosis if their BMD was $<$ -2.5 SD, and were diagnosed with osteopenia if their BMD was between -1.0 and -2.5 SD, and they were considered to have a normal BMD if their BMD was $>$ -1.0 SD.

**Grouped**

Type 2 diabetic patients were divided into groups according to the diabetes duration and hemoglobin A1c (HbA1c) level: the diabetes duration $\leq$ 10 years group and the diabetes duration $>$ 10 years group; the HbA1c $\leq$ 8% group and the HbA1c $>$ 8% group.
Biochemical measurements

All subjects were asked for details about their height and weight, and BMI was calculated. Elbow venous blood (5 ml) was collected from each subject in the morning after 8 hours of fasting. The HbA1c was measured with a TOSOH G7 analyzer, serum 25OHD was determined by enzyme immunoassay (EIA), and serum PTH was measured by a radioimmunoassay. Serum 25OHD levels less than 50 nmol/l can be defined as definitive vitamin D deficiency [24].

Statistical analysis

Data were analyzed using SPSS 19.0 software. Quantitative data were in accordance with normal distribution. Measurement data were expressed as the (x ± s). Homogeneity of variance using ANOVA analysis. Qualitative data using the chi-square test. The BMD-related factors were analyzed by simple correlation analysis. A P value <0.05 was considered statistically significant.

Results

Tables 1 and 2 show a comparison of general data and BMDs between various groups. There was no significant difference between diabetes and control subjects in terms of the age and BMI. The 25OHD levels and BMDs at the femoral neck and total hip were significantly lower in diabetes than those in control subjects (P<0.01 and P<0.05); however, the PTH levels

### Table 1. Comparison of general data and BMDs between various groups (x ± s).

| Groups         | N   | Age (years) | BMI (kg/m²) | 25OHD (nmol/L) | PTH (pmol/L) |
|----------------|-----|-------------|-------------|----------------|--------------|
| Control subjects | 300 | 60±12       | 25±5        | 45±17          | 5.6±3.9      |
| Diabetes       | 368 | 61±8        | 26±5        | 36±12*         | 8.5±4.2*     |
| Male of control subjects | 83  | 60±11       | 25±5        | 47±16          | 5.2±3.9      |
| Male of diabetes  | 121 | 60±9        | 27±5        | 36±13#         | 7.9±4.3#     |
| Female of control subjects | 217 | 58±11       | 24±4        | 44±18          | 5.8±3.9      |
| Female of diabetes  | 247 | 60±8        | 25±5        | 35±12#         | 8.9±4.1#     |

BMI- Body Mass Index; 25OHD-25-Hydroxyvitamin D; PTH-Parathyroid Hormone; P value <0.05 is considered significant.

Control subjects vs. diabetes *P<0.01; Male of control subjects vs. male of diabetes #P<0.05; Female of control subjects vs. female of diabetes #P<0.05.

https://doi.org/10.1371/journal.pone.0188894.t001

### Table 2. Comparison of general data and BMDs between various groups (x ± s).

| Groups         | BMD (g/cm²) | Lumbar spine(L1-L4) | Femoral neck | Total hip | Whole body |
|----------------|-------------|----------------------|--------------|-----------|------------|
| Control subjects | 1.10±0.21  | 0.93±0.17            | 0.93±0.14    | 0.93±0.14| 0.88±0.20  |
| Diabetes       | 1.05±0.19  | 0.85±0.14*           | 0.87±0.15#   | 0.98±0.09 | 0.98±0.09  |
| Male of control subjects | 1.15±0.22  | 1.01±0.16            | 0.94±0.13    | 0.93±0.19| 0.92±0.15  |
| Male of diabetes  | 1.08±0.17  | 0.91±0.11#           | 0.92±0.15    | 0.84±0.12#| 0.84±0.12# |
| Female of control subjects | 1.08±0.20  | 0.90±0.17            | 0.92±0.15    | 0.92±0.15| 0.92±0.15  |
| Female of diabetes  | 1.02±0.21  | 0.80±0.13*           | 0.83±0.16#   | 0.84±0.12#| 0.84±0.12# |

BMD-Bone Mineral Density; P value <0.05 is considered significant.

Control subjects vs. diabetes *P<0.01, #P<0.05; Male of control subjects vs. male of diabetes #P<0.05; Female of control subjects vs. female of diabetes #P<0.01, #P<0.05.

https://doi.org/10.1371/journal.pone.0188894.t002
Increased bone mineral density in type 2 diabetes.

Table 3. Comparison of 25OHD, PTH and BMDs between different diabetes duration groups (x²).  

| Group                  | N   | Age (years) | BMI (kg/m²) | 25OHD (nmol/L) | PTH (pmol/L) | Value of F |
|------------------------|-----|-------------|-------------|----------------|--------------|------------|
| Control group          | 300 | 60±12       | 25±5        | 45±17          | 5.6±3.9      |            |
| Diabetes duration≤10 years group | 246 | 60±8        | 26±5        | 39±16          | 7.1±3.7      |            |
| Diabetes duration>10 years group | 122 | 62±8        | 25±4        | 34±11*         | 10.6±9.1*#   |            |

BMI-Body Mass Index; 25OHD-25-Hydroxyvitamin D; PTH-Parathyroid Hormone; P value <0.05 is considered significant.

Compared with control group *P <0.05; compared with diabetes duration ≤10 years group #P<0.05.

https://doi.org/10.1371/journal.pone.0188894.t003

Table 4. Comparison of 25OHD, PTH and BMDs between different diabetes duration groups (x²).  

| Group                  | Lumbar spine | Femoral neck | Total Hip | Whole Body |
|------------------------|--------------|--------------|-----------|------------|
| Control group          | 1.10±0.21    | 0.93±0.17    | 0.93±0.14 | 0.93±0.14  |
| Diabetes duration≤10 years group | 1.08±0.18    | 0.88±0.11    | 0.91±0.14 | 0.92±0.20  |
| Diabetes duration>10 years group | 1.02±0.21    | 0.81±0.15*#  | 0.84±0.16*# | 0.85±0.19*  |

BMD-Bone Mineral Density.  
P value <0.05 is considered significant.

Compared with control subjects *P <0.05; compared with diabetes duration ≤10 years group #P<0.05.

https://doi.org/10.1371/journal.pone.0188894.t004
Table 5. Comparison of 25OHD, PTH and BMDs between different HbA1c groups (x**i**).  

| Group               | N    | Age (years) | BMI (kg/m²) | 25OHD (nmol/L) | PTH (pmol/L) |
|---------------------|------|-------------|-------------|----------------|--------------|
| Control group       | 300  | 60±12       | 25±5        | 45±17          | 5.6±3.9      |
| HbA1c≤8% group      | 184  | 60±8        | 26±5        | 40±15          | 7.2±4.0      |
| HbA1c>8% group      | 184  | 62±9        | 25±4        | 32±13**        | 10.0±8.8**   |

Value of F  

BMI- Body Mass Index; 25OHD-25-Hydroxyvitamin D; PTH-Parathyroid Hormone; P value <0.05 is considered significant. Compared with the control group *P<0.05; compared with the HbA1c ≤8% group *P<0.05.  

https://doi.org/10.1371/journal.pone.0188894.t005

Table 6. Comparison of 25OHD, PTH and BMDs between different HbA1c groups (x**i**).  

| Group               | BMD (g/cm²) | lumbar spine(L1-L4) | femoral neck | total hip | whole body |
|---------------------|-------------|---------------------|--------------|-----------|------------|
| Control group       | 1.10±0.21   | 0.93±0.17           | 0.93±0.14    | 0.93±0.14 |            |
| HbA1c≤8% group      | 1.04±0.19   | 0.89±0.13           | 0.95±0.13    | 0.89±0.15 |            |
| HbA1c>8% group      | 1.05±0.20   | 0.83±0.13**         | 0.83±0.16**  | 0.86±0.21*|            |

Value of F  

BMD-Bone Mineral Density; P value <0.05 is considered significant. Compared with the control group *P<0.05; compared with the HbA1c ≤8% group *P<0.05.  

https://doi.org/10.1371/journal.pone.0188894.t006

Table 7. Comparison of the proportion of osteoporosis, osteopenia and normal BMD between diabetes group and control group.  

| Group               | Osteoporosis | Osteopenia | Normal BMD |
|---------------------|--------------|------------|------------|
| Control group       | 81(27.0%)    | 100(33.3%) | 119(39.7%) |
| Diabetes group      | 151(41.0%)   | 176(47.8%) | 41(11.2%)  |

Value of χ²  

Value of P  

P value <0.05 is considered significant  

https://doi.org/10.1371/journal.pone.0188894.t007

Table 8. Comparison of all indexes at different BMD subgroups in diabetic patients.  

| Group               | N    | 25OHD (nmol/L) | PTH (pmol/L) | HbA1c (%) | Diabetes duration (years) |
|---------------------|------|----------------|--------------|-----------|--------------------------|
| Normal BMD group    | 41   | 41±18          | 7.2±3.7      | 8.3±2.2   | 9.2±6.7                  |
| Osteopenia group    | 176  | 34±13          | 7.5±2.7      | 8.7±2.0   | 11.0±6.5                 |
| Osteoporosis group  | 151  | 35±13          | 10.8±3.2**   | 10.0±2.8**| 14.9±7.3**               |

HbA1c-Hemoglobin A1c; PTH-Parathyroid Hormone; P value <0.05 is considered significant. Compared with the normal BMD group *P <0.05; compared with the osteopenia group *P <0.05  

https://doi.org/10.1371/journal.pone.0188894.t008
Table 9 shows a simple correlation analysis of the femoral neck BMD. The above results showed that the femoral neck BMD decreased the most sensitively; therefore, a simple correlation analysis was performed with the femoral neck BMD as the dependent variable, and diabetes duration, HbA1c, PTH and 25OHD levels as the independent variables. The results revealed that BMD at the femoral neck was negatively correlated with diabetes duration, HbA1c and PTH, whereas it was positively correlated with 25OHD (Table 9).

**Table 9. A single factor correlation analysis of the femoral neck BMD.**

| correlation factors | femoral neck |
|---------------------|--------------|
| Age (years)         | -0.18        |
| Diabetes duration (years) | -0.23        |
| HbA1c(%)            | -0.18        |
| PTH(pmol/l)         | -0.25        |
| 25OHD (nmol/l)      | 0.23         |

rs-correlation coefficient; HbA1c-Hemoglobin A1c; 25OHD-25-Hydroxyvitamin D; PTH-Parathyroid Hormone; P value <0.05 is considered significant

Table 9 shows a simple correlation analysis of the femoral neck BMD. The above results showed that the femoral neck BMD decreased the most sensitively; therefore, a simple correlation analysis was performed with the femoral neck BMD as the dependent variable, and diabetes duration, HbA1c, PTH and 25OHD levels as the independent variables. The results revealed that BMD at the femoral neck was negatively correlated with diabetes duration, HbA1c and PTH, whereas it was positively correlated with 25OHD (Table 9).

**Discussion**

Recently, Diabetes and osteoporosis are the two most common diseases in elderly individuals [4,10,20]. A lower BMD is a risk factor for osteoporosis and bone fractures [14]. The BMD level, however, is not fully understood, and there remains controversy over its value in diabetes. One study [22] reported that the BMD of the hip is lower in diabetes than in age and BMI-matched non-diabetes men. Another study [19] demonstrated that the BMD was lower in diabetic group than healthy control group, and a negative correlation was observed between the BMDs and both the serum glucose level and HbA1c. Our study found that the BMDs at the femoral neck and total hip were significantly lower in diabetic patients than those in control subjects, especially among women. However, male diabetic patients only presented with a significantly decreased BMD at the femoral neck. The proportions of osteoporosis and osteopenia were significantly higher in diabetes group than control subjects. Nearly half of diabetic patients had osteoporosis, whereas the proportions of osteoporosis plus osteopenia were as high as 88.8%. Our study showed that, there were a higher incidence of osteoporosis and a lower BMD value in Chinese type 2 diabetes, which should be aroused our attention. Similarly, an 11-year observational study [24] of 32,089 postmenopausal diabetic women demonstrated significantly decreased BMDs at the femoral neck and hip as well as significantly increased incidence of hip fracture in diabetic patients, which was 1.7 times that of the non-diabetes group. In another cross-sectional study of American men [25], comparison of the BMD between 3,458 non-diabetic controls and 735 type 2 diabetic patients also showed a significantly lower hip BMD and increased osteoporosis incidence in type 2 diabetes group than non-diabetes group. According to a 5-year follow-up longitudinal study of diabetic women without a history of osteoporosis by Hamilton et al. [26], showed that the BMD at all parts was significantly reduced compared with the BMD five years prior, except for the lumbar spine BMD. The above three studies [24–26] showed an unchanged or increased lumbar spine BMD. The lumbar spine BMD was mostly unchanged or increased, which may be due to the lumbar vertebrae propensity to hyperostosis, especially the vertebral edge hyperplasia and even bone bridge formation in the elderly which led to the measurement of false normal or lumbar spine BMD increased.
The influence of diabetes duration and HbA1c on the BMD were also observed in this study. Diabetes duration > 10 years group and HbA1c > 8% group had a significantly lower BMDs at the femoral neck and total hip than diabetes duration ≤ 10 years group and HbA1c ≤ 8% group, suggesting that there was a substantial influence of diabetes duration and control level of blood glucose on the BMD. Consistent with the foreign studies, to assess the BMD levels of type 2 diabetes, Majima [27] compared the BMDs of the cortical bone (distal radius) and cancellous bone (lumbar spine and femoral neck) and Z scores between 145 type 2 diabetes and 95 controls, which showed that the average HbA1c level was negatively correlated with the male and female proximal radius and the female femoral neck BMD. However, Zhang et al.’s report [28] found no correlation between the BMD and HbA1c in male diabetic patients. For each additional 15 years of diabetes duration, the BMD will be reduced by 10% according to Kown et al [29]. Janghorbani et al [30] reported that the longer the duration of diabetes, the higher the risk of hip fracture; in addition, for type 2 diabetes duration ≥ 10 years, the risk of hip fracture was 2.7 times that of the non-diabetes group. We also compared the diabetes duration and HbA1c level at different bone mass distributions, which revealed that the average diabetes duration and HbA1c reached 14.9 years and 10.0%, respectively, in diabetic osteoporosis group, which were significantly higher than osteopenia group and normal BMD group. Additionally, we performed a single factor correlation analysis of the femoral neck BMD and found that the diabetes duration and HbA1c were both negatively correlated with the femoral neck BMD.

It is well known that the important factors influencing BMD level are 25OHD, PTH hormone level. In this study, a significantly lower 25OHD level was observed in diabetics group than those in control group. As the researches abroad [31] the 25OHD level was significantly lower in diabetes duration > 10 years group and HbA1c > 8% group than that in control group. Correlation analysis showed a positive correlation between the 25OHD level and BMD, consistent with the foreign research [14, 32]. Bischoffferrari, et al [14] also observed a significant positive association between serum 25OHD and BMD in individuals with primary knee OA. Akhter et al [33] analyzed 112 African American men for the 25OHD level and BMD and found that those with serum 25OHD levels lower than 10 ng/ml and 30 ng/ml accounted for 24% and 89%, respectively; in addition, when 25OHD2 was lower than 15 ng/ml, the 25OHD level was positively correlated with the BMD. Given the high prevalence of low 25OHD status in diabetes, and the positive association between 25OHD and BMD, vitamin D supplementation may enhance BMD in individuals with diabetes. One classical pathway of CYP11A1 to metabolize D3 was: D3 → 25OHD → 1,25(OH)2D3. Recent study showed that skin cells can metabolize D3 through the novel CYP11A1 initiated pathway, as an additional and alternative pathway to the classical one, where showed a slightly higher production of 1,25(OH)2D3 to improve Vitamin D level [34,35]. The novel pathways of D3 metabolism initiated by CYP11A1 and modified by CYP27B1 activity, these findings define the pathway intermediates (include 20(OH)D3, 22(OH)D3, 20,23(OH)(2)D3, 1,20(OH)(2)D3 etc.) as natural products/endogenous bioregulators and break the current dogma that vitamin D is solely activated through the sequence 3D → 25(OH)D3 → 1,25(OH)(2)D3 [36,37].

Research on the action of vitamin D (VitD) on bone mechanisms has been increasing; in addition to having classic effects on bone, recent studies have shown that VitD also has a role in bone formation as well as a facilitating role in collagen generation and osteoblasts. Bone formation decreased under the diabetes state, while bone resorption increased compared to bone formation; furthermore, in the diabetes population, vitamin D receptor (VDR) gene polymorphism was also closely associated with BMD [38]. Vitamin D insufficiency is associated with increased PTH levels, accelerated cortical bone loss and an increased risk of fractures, and concluded the relationship between PTH and 25OHD decreases smoothly [39]. In our study, PTH
was significantly higher in diabetes group than control group, and it was significantly higher in diabetic osteoporosis group than osteopenia group and normal BMD group. Correlation analysis demonstrated that PTH level was negatively correlation with the femoral neck BMD. Among 368 type 2 diabetes, 70 (59.8%) had an elevated PTH level. The study by Nagasaka et al [40] showed that long-term hyperglycemia in type 2 diabetes leads to hypocalcemia, and stimulating PTH secretion, which may be the cause of osteopenia among diabetic patients. The improvement of glucose metabolism may be somewhat helpful in reducing the PTH level. Chen et al [41] found that the rate of PTH level increased was over 30% among elderly fracture patients, but they did not find any correlation between PTH level and BMD. PTH secretion can be directly regulated by the VitD level and blood calcium. In the earlier period, PTH elevation may be stimulated by a lower VitD level and lower blood calcium and it would reduce bone formation. In later period, increased PTH further enhances osteoclast activity, leading to increased bone resorption and further reduction of the BMD.

In summary, the BMD is influenced by many factors, such as genetic factors and non-genetic factors, especially geographic and environmental factors; changes in diet and exercise; nutritional, obesity and metabolic changes; medication, etc. The timely detection of serum 25OHD level and BMD should be taken seriously. Patients with a diabetes duration > 10 years and consistent HbA1c > 8% and who are over 50 years of age should be evaluated for their BMD and 25OHD level as early as possible. Numerous studies have demonstrated the non-negligible influence of diabetes mellitus on BMD, including diabetes duration and glycemic control level. Strict glycemic control is also very necessary for preventing osteoporosis and fractures. Vitamin D supplementation may enhance BMD in individuals with diabetes. Some study suggested that a high dose daily intake of 4000IU vitamin D to maintain 25OHD ranged from 100–150 nmol/l. This study was limited by the smaller sample size; we would increase the sample to have a vitamin D supplementation dose in the next study.

Supporting information
S1 Appendix. Basic information of all subjects.
(XLS)

S2 Appendix. CONSORT checklist.
(DOC)

S3 Appendix. Trial protocol.
(DOC)

S4 Appendix. Consent form.
(DOC)

S5 Appendix. Case report form.
(DOC)

S1 Fig. Flowchart of participates’ progress through the phases of the trial.
(DOCX)

Acknowledgments
The author would like to thank all the participants in the General Hospital of Tianjin Medical University and Teda International Cardiovascular Hospital.
Thanks for all the subjects for their cooperation.
Author Contributions

Data curation: Liting Guo, Zhihong Gao, Huanqi Ge.
Investigation: Liting Guo, Zhihong Gao.
Methodology: Liting Guo, Huanqi Ge.
Project administration: Liting Guo.
Resources: Liting Guo.
Software: Liting Guo.
Supervision: Zhihong Gao.
Writing – original draft: Liting Guo.
Writing – review & editing: Liting Guo.

References

1. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults[J]. Jama the Journal of the American Medical Association. 2013; 310(9):948–959. https://doi.org/10.1001/jama.2013.168118 PMID: 24002281
2. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?[J]. Osteoporosis International. 2009; 20(2):197–207. https://doi.org/10.1007/s00198-008-0648-5 PMID: 18509713
3. Yacov F, Inbal G, Elena S, Sofia IS. Managing Osteoporosis: A Survey of Knowledge, Attitudes and Practices among Primary Care Physicians in Israel[J]. Plos One.2016; 11(8):e0160661. https://doi.org/10.1371/journal.pone.0160661 PMID: 27494284
4. Hovi P, Andersson S, Järvenpää AL, Eriksson JG, Strangkarlsson S, Kajantie E, et al. Decreased bone mineral density in adults born with very low birth weight: a cohort study[J]. Plos Medicine.2009; 6(8): e1000135. https://doi.org/10.1371/journal.pmed.1000135 PMID: 19707270
5. Zhang Z, Liu Z, Shi S, Yanning LI. A retrospective literature study of osteoporosis incidence based on-2.5 SD criteria in mainland China[J]. Chinese Journal of Osteoporosis. 2015;1(1):3–7
6. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the women's health initiative observational study. Journal of Clinical Endocrinology & Metabolism[J]. 2006; 91(8):3404–3410.
7. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture[J]. American Journal of Epidemiology. 2007; 166(5): 495. https://doi.org/10.1093/aje/kwm106 PMID: 17575306
8. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older women with diabetes have an increased risk of fracture: a prospective study[J]. Clin Endocrinol Metab.2001; 86 (1):32–38.
9. Lipcombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care. 2007; 30(4):835. https://doi.org/10.2337/dc06-1851 PMID: 17392544
10. Koh WP, Wang R, Ang LW, Heng D, Yuan JM, Yu MC. Diabetes and risk of hip fracture in the Singapore Chinese Health Study[J]. Diabetes Care. 2010; 33(8):1766–1770. https://doi.org/10.2337/dc10-0067 PMID: 20504896
11. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med.1992; 327(23):1637. https://doi.org/10.1056/NEJM199212033272305 PMID: 13317988
12. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin d3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the decalyos II study. Osteoporosis International.2002; 13(3):257–264. https://doi.org/10.1007/s001980200023 PMID: 11991447
13. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med.1977; 337:670–676.
14. Bischoffferrari HA, Zhang Y, Kiel DP, Felson DT. Positive association between serum 25-hydroxyvitamin d level and bone density in osteoarthritis. Arthritis Care & Research.2005; 53(6):821–826.
15. Bartl R, Frisch B. Bone Mineral Density (BMD): The Crucial Diagnostic Parameter[M]. Osteoporosis. 2004:58–72.

16. Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, et al. Prediction of osteoporotic fractures by postural instability and bone density. 1993; 307(6912):1111–1115.

17. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. American Journal of Epidemiology. 1996; 144(3):255–263. PMID: 8686694.

18. Johnell O, Kanis JA, Oden A, Johansson H, De LC, Delmas P, et al. Predictive value of bmd for hip and other fractures. Journal of Bone & Mineral Research. 2005; 20(7):1185.

19. Loureiro MB, Ururahy MA, Freireneto FP, Oliveira GH, Duarte VM, Luchessi AD, et al. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes[J]. Diabetes Research & Clinical Practice. 2010; 99(9):683–690.

20. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women[J]. Diabetes Care. 2004; 27(7):1419–1425. PMID: 15200112.

21. Slominski AT, Kim TK, Shehabi HZ, Semak I, Tang EKY, Nguyen MN, et al. In vivo evidence for a novel pathway of vitamin D metabolism initiated by P450scC and modified by CYP27B1[J]. Faseb Journal.
Official Publication of the Federation of American Societies for Experimental Biology, 2012; 26 (9):3901–3915. https://doi.org/10.1096/fj.12-208975 PMID: 22683847

37. Slominski AT, Kim TK, Li W, Tuckey RC, et al. Classical and non-classical metabolic transformation of vitamin D in dermal fibroblasts.[J]. Experimental Dermatology, 2016; 25(3):231. https://doi.org/10.1111/exd.12872 PMID: 26440881

38. Dong Y, Zhai M, Changgui LI, Wang H, Liu L, Ning QU, et al. Association of vitamin D receptor gene polymorphism with bone mineral density in the patients with diabetes mellitus[J]. Chinese Journal of Endocrinology & Metabolism. 2002; 18 (2):111–115.

39. Valcour A, Blocki F, Hawkins DM, Rao SD. Effects of age and serum 25-OH-vitamin d on serum parathyroid hormone levels. Journal of Clinical Endocrinology & Metabolism. 2012; 97(11):3989–3995.

40. Nagasaki S, Murakami T, Uchikawa T, Ishikawa SE, Saito T. Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus.[J]. Endocrine Journal. 1995; 42(3):377–83. PMID: 7670567

41. Chen H, Feng F. Correlation between serum 25-hydroxy vitamin D, parathyroid hormone and osteoporosis in elderly fracture population[J]. Chinese Journal Of Osteoporosis & Bone Mineral Research. 2013; 6(1):20–27. https://doi.org/10.4061/2011/729219